Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 16/20 | 1.00 |
| ▸ | BRAF | P15056 | 16/20 | 1.00 |
| ▸ | KDR | P35968 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890486 | 0.91 | RAF1 (0.83) | RAF1BRAFKDR | |
| SCHEMBL2893460 | 0.91 | BRAF (1.00) | RAF1BRAFKDR | |
| SCHEMBL2895534 | 0.90 | BRAF (1.00) | RAF1BRAFKDR | |
| SCHEMBL4363224 | 0.90 | BRAF (1.00) | RAF1BRAFKDR | |
| SCHEMBL2893502 | 0.90 | BRAF (0.93) | RAF1BRAFKDR | |
| SCHEMBL2890473 | 0.90 | BRAF (0.81) | RAF1BRAFKDR | |
| SCHEMBL4362170 | 0.89 | RAF1 (0.80) | RAF1BRAFKDR | |
| SCHEMBL3010947 | 0.89 | RAF1 (1.00) | RAF1BRAFKDR | |
| SCHEMBL1217970 | 0.89 | RAF1 (1.00) | RAF1BRAFKDR | |
| SCHEMBL2891216 | 0.88 | BRAF (1.00) | RAF1BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614330-B2 | Substituted benz-azoles and methods of their use as inhibitors of RAF kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20100196368-A1 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196368-A1 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196368-A1 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| EP-1499311-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| US-7071216-B2 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885KDR 1078/4885 |
| US-20100196368-A1 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885KDR 891/4885 |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885KDR 891/4885 |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | RAF1 1846/4885BRAF 612/4885KDR 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.